Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedMay 15, 2019Carvedilol TabletsLabeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mgZydus Pharmaceuticals USA Inc · D-1273-2019Class IITerminatedMay 15, 2019Acyclovir TabletsLabeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mgZydus Pharmaceuticals USA Inc · D-1272-2019Class IIITerminatedMay 8, 2019Dermoplast Anesthetic PAIN & ITCHLabeling: Not Elsewhere Classified: Full cases may contain canisters that incorrectly state the net weight is 2.75 oz. rather than the correct net weight of 2.0 oz.Advantice Health · D-1280-2019Class IIITerminatedMay 8, 2019Dermoplast Anesthetic PAIN & ITCHLabeling: Not Elsewhere Classified: canisters incorrectly state the net weight is 2.75 oz. rather than the correct net weight of 2.0 oz.Advantice Health · D-1279-2019Class IITerminatedMay 8, 2019GlipiZIDE Extended-release TabletsFailed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.American Health Packaging · D-1276-2019Class IITerminatedMay 8, 2019RevontoPresence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.US Worldmeds LLC · D-1275-2019Class IITerminatedMay 8, 2019BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by...Defective Delivery System: difficult to expressPacifico National, Inc. dba AmEx Pharmacy · D-1271-2019Class IITerminatedMay 8, 2019Losartan Potassium/HCTZCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of...RemedyRepack Inc. · D-1270-2019Class IIOngoingMay 8, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1269-2019Class IIOngoingMay 8, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1268-2019Class IIOngoingMay 8, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1267-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1266-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1265-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1264-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)Legacy Pharmaceutical Packaging LLC · D-1263-2019Class IITerminatedMay 8, 2019TriMix MEDIUMLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1262-2019Class IITerminatedMay 8, 2019Trimix HIGHLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1261-2019Class IITerminatedMay 8, 2019Test PROCYPLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1260-2019Class IITerminatedMay 8, 2019Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1259-2019Class IITerminatedMay 8, 2019Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1258-2019Class IITerminatedMay 8, 2019LipoplexLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1257-2019Class IITerminatedMay 8, 2019HCG (CHORIONIC GONADOTROPIN 1000 IU/ML PEP 25 mg/mL) inj 5 mL multidose vial compounded. Customceutical...Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1256-2019Class IITerminatedMay 8, 2019Glutathione 200mg/mL inj. a) 10 ML and b) 12 ML MULTIDOSE VIAL MDV Compounded. Customceutical Compounding...Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1255-2019Class IITerminatedMay 8, 2019BPlex (METHYLCOBALAMIN 1000 MCG/ML PYRIDOXAL 5 PHOSPHATE 20MG/ML DEXPANTHENOL 250MG/ML)Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1254-2019Class IITerminatedMay 8, 2019BPlex (METHYLCOBALAMIN 1000 MCG/ML PYRIDOXAL 5 PHOSPHATE 20MG/ML DEXPANTHENOL 250MG/ML)Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1253-2019Class IITerminatedMay 8, 2019HYDROmorphone 20 mg/100 mL Injectable SolutionSub-potencyAdvanced Pharma Inc. · D-1251-2019Class IIOngoingMay 8, 2019Losartan Potassium Tablets USP 25 mg 50 tabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of...AVKARE Inc. · D-1250-2019Class IIOngoingMay 8, 2019Losartan Potassium Tablets USP 50 mg 50 tabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of...AVKARE Inc. · D-1249-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1247-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1246-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1245-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1244-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1243-2019Class IIITerminatedMay 1, 2019Carvedilol TabletsPresence of Foreign Tablets/Capsules: Customer complaint for a small, solid, light yellow substance, identified as a fragmented tablet of another drug product, found...Zydus Pharmaceuticals USA Inc · D-1242-2019Class IIITerminatedMay 1, 2019Fentanyl Citrate InjectionFailed impurities/degradation specification: Out of Specification result for total impurity at 4.0% (Limit: NMT 3.0%) at 12 months stability testing.Akorn Inc · D-1241-2019Class IITerminatedMay 1, 2019DelNido CardioplegiaLack of sterility assurance.CMC Enterprise Pharmacy · D-1240-2019Class IITerminatedMay 1, 2019Vancomycin 2000 mg in 0.9% Sodium Chloride 500 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1239-2019Class IITerminatedMay 1, 2019Vancomycin 1750 mg in 0.9% Sodium Chloride 500 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1238-2019Class IITerminatedMay 1, 2019Vancomycin 1500 mg in NS 250 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1237-2019Class IITerminatedMay 1, 2019Vancomycin 1250 mg in NS 250 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1236-2019